Analysis of the efficacy of thalidomide plus dexamethasone-based regimens in patients with relapsed/refractory multiple myeloma who received prior chemotherapy, including bortezomib and lenalidomide: KMM-166 study
ConclusionThalidomide-based regimens are potential salvage treatment options for patients with RRMM, even with prior resistance to IMiDs.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Anemia | Brain | Cancer & Oncology | Chemotherapy | Dexamethasone | Hematology | Leukemia | Lymphoma | Myeloma | Neurology | Peripheral Neuropathy | Revlimid | Study | Toxicology | Velcade